Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of JR-171-101 in Patients With Mucopolysaccharidosis Type I
jRCT2051210040Active, not recruiting
- Sponsor
- JCR Pharmaceuticals
- Start
- Oct 2021
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of pabinafusp alfa in mucopolysaccharidosis type I, sponsored by JCR Pharmaceuticals. Primary endpoints: Frequency and severity of adverse events and their relationship to JR-171, Changes in laboratory parameters and 4 more. Started Oct 2021; status: active, not recruiting.
02
Drugs
pabinafusp alfa
03
Conditions
mucopolysaccharidosis type I
Beyond the preview
Go deeper on jRCT2051210040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210040.